DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Bill Anders"


8 mentions found


☆ Bayer's new CEO has a full in-tray as investors push for change
  + stars: | 2023-02-09 | by ( ) www.reuters.com   time to read: +5 min
February 9 - By Ludwig Burger and Patricia WeissFRANKFURT (Reuters) - Bayer's incoming CEO is inheriting a full in-tray from his predecessor: Thousands of lawsuits claiming its weedkiller causes cancer, an underwhelming drug development pipeline and disgruntled investors looking for major change. "The most important task for Bill Anderson is to regain investors' trust," said Markus Manns, a portfolio manager at Germany's Union Investment, a top 20 shareholder. Bayer's shares lag those of its global rivals, having fallen about 40% - knocking about 30 billion euros off its market valuation - since it bought Monsanto in 2018 for about $63 billion. Baumann's early exit has stirred debate about what the 56-year-old Anderson can do to restore investor trust and boost Bayer's shares. A stand-alone pharmaceuticals business, with 18.3 billion euros in 2021 sales, could also become a takeover target.
☆ German union opposes Bayer split after CEO departure - taz newspaper
  + stars: | 2023-02-09 | by ( ) www.reuters.com   time to read: +1 min
BERLIN, Feb 9 (Reuters) - Germany's IGBCE union opposes any splitting-up of Bayer after the departure of its chief executive and warned that the company should not bow to pressure from hedge fund activism, taz newspaper reported on Thursday. "From the point of view of the employees, Bayer with its three pillars is perfectly positioned for the challenges of the future," said IGBCE executive board member Francesco Grioli, who is also a member of the supervisory board at Bayer. The company currently has three divisions - pharmaceuticals, consumer health and crop science. "You can only manage the transformation of the industry with a corporate policy based on risk diversification and sustainability - not on hedge fund activism," Grioli told taz. Bayer announced on Wednesday that it was replacing its CEO early, recruiting the former head of Roche's pharmaceuticals business, as investor criticism over the company’s lacklustre share price grew.
☆ Bayer Hires Former Roche Executive to Succeed CEO Werner Baumann
  + stars: | 2023-02-08 | by ( William Boston | Patrick Thomas | ) www.wsj.com   time to read: 1 min
Bill Anderson is set to join Bayer’s management board in April and become CEO in June. BERLIN— Bayer AG said it is replacing the company’s embattled chief executive, Werner Baumann , with Bill Anderson, a 56-year-old American pharmaceuticals executive. Mr. Baumann, 60 years old, has served as CEO since 2016 after previously serving as the company’s finance chief. His current term was due to expire in April 2024. He led the company’s acquisition of Monsanto for $63 billion in 2018, which left Bayer mired in litigation and saddled with about $43 billion in debt.
☆ Factbox: Bayer's new CEO: long-time Roche, Genentech executive, Bill Anderson
  + stars: | 2023-02-08 | by ( ) www.reuters.com   time to read: +1 min
LONDON, Feb 8 (Reuters) - Bayer (BAYGn.DE) bowed to investor pressure on Wednesday and named Bill Anderson, most recently head of Roche's (ROG.S) pharmaceuticals business, to take over from Werner Baumann as its CEO in June. Here are some key facts about the career about the 56-year-old American who will run the nearly 160-year-old German drugmaker:He is a chemical engineer by education and has worked for Genentech and its parent Roche since 2006CAREER:1989: started his career at Ethyl Corp, a U.S.-based fuel additives company, with postings in Belgium and the Netherlands1995: joined Raychem Corp., a U.S. technology and electronics firm1997-2006: worked at Biogen (BIIB.O) in the United States, UK and Ireland; roles included running its neurology unit, its largest business2006: joined Genentech as senior vice president, immunology and ophthalmology2010: became svp BioOncology2013: left Genentech to become global product strategy head/chief marketing officer at Genentech's parent company, Roche (ROG.S)2016: returned to Genentech as head of North American operations2017: appointed chief executive officer at Genentech2019-2023: CEO of Roche PharmaceuticalSources: Roche and BayerCompiled by Josephine Mason. Editing by Jane MerrimanOur Standards: The Thomson Reuters Trust Principles.
☆ Bayer picks outsider Anderson as CEO after investor pressure
  + stars: | 2023-02-08 | by ( ) www.reuters.com   time to read: +2 min
News of the CEO change sent the German drugs-to-pesticides giant's shares to their highest level in nearly eight months. Shares in Bayer closed up 6% on the news of the new CEO, reaching the top of Frankfurt's blue-chip index and hitting their highest level since June last year. "Bill Anderson's mission is clear: enable Bayer to realize its full potential and create sustainable value for our shareholders, farmers, patients, consumers, employees, and all stakeholders of the company," Winkeljohann added. Sources told Reuters earlier this week that activist investor Jeff Ubben had contacted fellow investors to drum up support for big changes at Bayer, including the swift replacement of Baumann. Reporting by Patricia Weiss, Kirsti Knolle and Christoph Steitz; Editing by Tom Sims and Alexander SmithOur Standards: The Thomson Reuters Trust Principles.
☆ Roche flags 2023 earnings decline on slump in COVID products
  + stars: | 2023-02-02 | by ( Ludwig Burger | ) www.reuters.com   time to read: +1 min
Last year, group revenue edged 1% higher to 63.3 billion Swiss francs ($69.78 billion), the company reported, beating market expectations of 63.2 billion francs, while core operating profit gained 1% to 22.2 billion Swiss francs, just shy of the average analyst estimate of 22.4 billion francs. The onus to reinvigorate the pipeline will be on chief executive officer-designate Thomas Schinecker, who is Roche's head of diagnostics, and due to be promoted to group CEO in March. In the wake of Schinecker's appointment, the head of Roche's pharmaceuticals division, Bill Anderson, decided in December to leave after 16 years with the Swiss drugmaker. Roche said on Thursday that Teresa Graham, currently Head of Global Product Strategy for Roche Pharmaceuticals, would succeed Anderson. ($1 = 0.9071 Swiss francs)Reporting by Ludwig Burger; Editing by Paul Carrel and Rashmi AichOur Standards: The Thomson Reuters Trust Principles.
☆ Roche's head of pharmaceuticals to leave company
  + stars: | 2022-12-12 | by ( ) www.reuters.com   time to read: +1 min
ZURICH, Dec 12 (Reuters) - Roche's (ROG.S) head of its pharmaceuticals division will leave the drugmaker at the end of the year, the Swiss company said on Monday, as it confirmed other parts of its succession plan. Former Genentech boss Bill Anderson "has decided to pursue opportunities outside of Roche," Roche said, with a successor due to be named by March 2023. Schinecker will replace Severin Schwan, who is slated to become chairman after 14 years as CEO of Roche. He has been instrumental in shaping Roche’s transformation and I wish him all the best for the future," Schwan said in a statement. He had been CEO of Roche's pharmaceuticals business since 2019.
☆ The fascinating story behind 'Earthrise' — the most famous picture of Earth ever taken — which turns 54 today
  + stars: | 2018-12-24 | by ( Dina Spector | Kelsey Vlamis | ) www.businessinsider.com   time to read: +4 min
"Earthrise" is the first image of Earth captured by humans from space. The photo of Earth was taken aboard Apollo 8 on December 24, 1968, by lunar module pilot Bill Anders. Sign up for our newsletter to get the latest on the culture & business of sustainability — delivered weekly to your inbox. The mission was historic, but equally memorable was the famous "Earthrise" photo that resulted, showing Earth rising above the lunar landscape. "Space rookie William Anders, however, was in charge of taking the photos.
<< prev 1 next >>
Total: 8